

Publications February 2023 – June 2024

1. Barber J, Al-Majdoub ZM, Couto N, Howard M, Elmorsi Y, Scotcher D, Alizai N, de Wildt S, Stader F, Sepp A, Rostami-Hodjegan A, Achour B (2023). Toward Systems-Informed Models for Biologics Disposition: Covariates of the Abundance of the Neonatal Fc Receptor (FcRn) in Human Tissues and Implications for Pharmacokinetic Modelling. *Eur J Pharm Sci*. doi: 10.1016/j.ejps.2023.106375.
2. Mostafa S, Polasek TM, Bousman C, Rostami-Hodjegan A, Sheffield LJ, Everall I, Pantelis C, Kirkpatrick CMJ (2022) Delineating gene-environment effects using virtual twins of patients treated with clozapine. *CPT Pharmacometrics Syst Pharmacol*. 2022 doi: 10.1002/psp4.12886.
3. Vasilogianni AM, Al-Majdoub ZM, Achour BA, Peters SA, Rostami-Hodjegan A, Barber J (2023). Proteomic Quantification of Receptor Tyrosine Kinases Involved in the Development and Progression of Colorectal Cancer Liver Metastasis. *Front Oncol*. DOI: 10.3389/fonc.2023.1010563
4. Hermann R, Rostami-Hodjegan A, Zhao P, Ragueneau-Majlessi I (2023). Seeing What Is Behind the Smokescreen: A Systematic Review of Methodological Aspects of Smoking Interaction Studies over the Last Three Decades and Implications for Future Clinical Trials. *Clinical and Translational Science*. DOI: 10.1111/cts.13494
5. Yau E, Gertz M, Ogungbenro K, Aarons L, Olivares-Morales (2023). A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models. *CPT Pharmacometrics Syst Pharmacol*. DOI: 10.1002/psp4.12915.
6. Aldibani HKA, Rajput AJ, Rostami-Hodjegan, A (2023). In-Depth Analysis of Patterns in Selection of Different Physiologically-Based Pharmacokinetic Modeling Tools: Part II - Assessment of Model Reusability and Comparison Between Open and Non-Open Source-Code Software. *Biopharmaceutics & Drug Disposition*. doi: 10.1002/bdd.2360.
7. Church S, Hyrich KL, Ogungbenro K, Unwin RD, Barton A, Bluett J (2023). Development of a sensitive biochemical assay for the detection of tofacitinib adherence. *Anal Methods*; 15(14):1797-1801. doi: 10.1039/d2ay01800d.
8. Melillo N, Scotcher D, Kenna JG, Green C, Hines CDG, Laitinen I, Hockings PD, Ogungbenro K, Gunwhy ER, Sourbron S, Waterton JC, Schuetz G, Galetin A (2023). Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats. *Pharmaceutics* 15(3):896. doi: 10.3390/pharmaceutics15030896.
9. Rajput AJ, Aldibani HKA, Rostami-Hodjegan, A (2023). In-Depth Analysis of Patterns in Selection of Different Physiologically-Based Pharmacokinetic Modeling Tools: Part I - Applications and Rationale Behind the Use of Open Source-Code Software. *Biopharmaceutics & Drug Disposition*. doi: 10.1002/bdd.2357
10. Yau E, Olivares-Morales A, Ogungbenro K, Aarons L, Gertz M (2023). Investigation of simplified physiologically-based pharmacokinetic models in rat and human. *CPT Pharmacometrics Syst Pharmacol*;12(3):333-345. doi: 10.1002/psp4.12911.
11. Cleary Y, Kletzl H, Grimsey P, Heinig K, Ogungbenro K, Baumann HES, Frey N, Aarons L, Galetin A, Gertz M (2023). Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdipam and Its Impact on Drug-Drug Interactions in Children. *Clin Pharmacokinet*. doi: 10.1007/s40262-023-01241-7.
12. Cristofolletti R, Rostami-Hodjegan A. (2023) Linking in vitro-in vivo extrapolations with physiologically based modeling to inform drug and formulation development. *Biopharm Drug Dispos*. 44(4):289-291. doi: 10.1002/bdd.2375.
13. El-Khateeb E, Chinnadurai R, Al Qassabi J, Scotcher D, Darwich AS, Kalra PA, Rostami-Hodjegan A. (2023) Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical

Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease. *Ther Drug Monit.* doi: 10.1097/FTD.0000000000001108.

14. Han C, Sun T, Chirumamilla SK, Bois FY, Xu M, Rostami-Hodjegan A. (2023) Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling. *Pharmaceutics.* doi: 10.3390/pharmaceutics15092237.
15. Hermann R, Rostami-Hodjegan A, Zhao P, Ragueneau-Majlessi I. (2023) Seeing what is behind the smokescreen: A systematic review of methodological aspects of smoking interaction studies over the last three decades and implications for future clinical trials. *Clin Transl Sci.* 16(5):742-758. doi: 10.1111/cts.13494.
16. Izat N, Bolleddula J, Abbasi A, Cheruzel L, Jones RS, Moss D, Ortega-Muro F, Parmentier Y, Peterkin VC, Tian D-D, Venkatakrishnan K, Zientek MA, Barber J, Houston JB, Galetin A, and Scotcher D (2023) Challenges and opportunities for in vitro-in vivo extrapolation of aldehyde oxidase-mediated clearance: Towards a roadmap for quantitative translation. *Drug Metab Dispos.* <https://doi.org/10.1124/dmd.123.001436>
17. Tan PFS, Willemin ME, Snoeys J, Shen H, Rostami-Hodjegan A, Scotcher D, Galetin A. (2023) Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease. *Clin Pharmacol Ther.* doi: 10.1002/cpt.3029
18. Mostafa S, Rafizadeh R, Polasek TM, Bousman CA, Rostami-Hodjegan A, Stowe R, Carrion P, Sheffield LJ, Kirkpatrick CMJ. Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. *CPT Pharmacometrics Syst Pharmacol.* 2024. doi: 10.1002/psp4.13093
19. Tsakalozou E, Fang L, Bi Y, van den Heuvel M, Ahmed T, Tsang YC, Lionberger R, Rostami-Hodjegan A, Zhao L. Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products-a Meeting Report. *AAPS J.* 2024. 10;26(1):14. doi: 10.1208/s12248-023-00884-5
20. Han C, Sun T, Chirumamilla SK, Bois FY, Xu M, Rostami-Hodjegan A. Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling. *Pharmaceutics.* 2023. 15(9):2237. doi: 10.3390/pharmaceutics15092237
21. Vasiogianni, AM, Alrubia S., El-Khateeb, E., Al-Majdoub, SM., Couto, N., Achour, B., Rostami-Hodjegan, A., Barber, J., Complimentarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transfers in the human liver, *Mol Omics* 2023. doi: 0.1039/D3MO00144J
22. Tan, SPF., Willemin, ME., Snoeys, J., Shen, H., Rostami-Hodjegan, A., Scotcher, D., Galetin, A., Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease, *Clin Pharmacol Ther* 2023 Dec 114(6):1243-1253. doi:10.1002/cpt.3029
23. Hodson D, Mistry H, Guzzetti S, Davies M, Staniszevska A, Farrington P, Cadogan E, Yates J, Aarons L, Ogungbenro K. Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway. *CPT Pharmacometrics Syst Pharmacol.* 2023 Nov;12(11):1640-1652. doi: 10.1002/psp4.13026.
24. Francis L, Ogungbenro K, De Bruyn T, Houston JB, Hallifax D. Exploring the boundaries for in vitro-in vivo extrapolation: use of isolated rat hepatocytes in co-culture and impact of albumin binding properties in the prediction of clearance of various drug types. *Drug Metab Dispos.* 2023 Nov;51(11):1463-1473. doi: 10.1124/dmd.123.001309.
25. Hodson D, Mistry H, Yates J, Farrington P, Staniszevska A, Guzzetti S, Davies M, Aarons L, Ogungbenro K. Radiation in combination with immune checkpoint blockade and DNA damage response inhibitors in mice: dosage optimization in MC38 syngeneic tumors via modelling and simulation. *J Pharmacol Exp Ther.* 2023 Oct;387(1):44-54. doi: 10.1124/jpet.122.001572.

26. Nørgaard RA, Bhatt DK, Järvinen E, Stage TB, Gabel-Jensen C, Galetin A, Säll C (2023) Evaluating drug-drug interaction risk associated with peptide analogues using advanced in vitro systems. *Drug Metab Dispos.* doi: 10.1124/dmd.123.001441.
27. Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sjöstedt N, Aleksunes L, Chu X, Evers R, Hafey MJ, Lai Y, Matsson P, Riselli A, Shen H, Sparreboom A, Varma MVS, Yang J, Yang X, Yee SW, Zamek-Gliszczynski MJ, Zhang L, Giacomini KM. (2024) Membrane transporters in drug development and as determinants of precision medicine. *Nat Rev Drug Discov.* doi: 10.1038/s41573-023-00877-1
28. Milani N, Parrott N, Galetin A, Fowler S and Gertz M. In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design *CPT PSP* 2024,13(4):524-543 doi: 10.1002/psp4.13110
29. Al-Qassabi J, Tan SPF, Phonboon P, Galetin A, Rostami-Hodjegan A, Scotcher D. Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations? *J Pharm Sci.* 2024 113(6):1664-1673 doi: 10.1016/j.xphs.2024.02.024
30. Rostami-Hodjegan A, Al-Majdoub ZM, von Grabowiecki Y, Yee KL, Sahoo S, Breitwieser W, Galetin A, Gibson C, Achour B. Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof-of-Concept Application of Liquid Biopsy in Renal Impairment. *Clin Pharmacol Ther.* 2024 doi: 10.1002/cpt.3291.
31. Prasad B, Al-Majdoub ZM, Wegler C, Rostami-Hodjegan A and Achour B. Quantitative Proteomics for Translational Pharmacology and Precision Medicine: State of The Art and Future Outlook. *DMD-AR-2023-001600* doi:10.1124/dmd.124.001600
32. Maestre JM, Chanfreuty P, Aarons L. Constrained numerical deconvolution using orthogonal polynomials. *Heliyon* 2024 doi: 10.1016/j.heliyon.2024.e24762.
33. Hodson D, Mistry H, Yates J, Guzzetti S, Davies M, J, Aarons L, Ogungbenro K. Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancer. *Eur J Pharm Sci.* 2024 Jun 1; 197:106774. doi: 10.1016/j.ejps.2024.106774
34. Hansel J, Mannan F, Robey R, Kumarendran M, Bladon S, Mathioudakis AG 1 5, Ogungbenro K, Dark P, Felton TW. Covariates in population pharmacokinetic studies of critically ill adults receiving β -lactam antimicrobials: a systematic review and narrative synthesis. *JAC Antimicrob Resist.* 2024 Feb 26; 6(1) :dlae030. doi: 10.1093/jacamr/dlae030.
35. Rostami-Hodjegan A. Conducting Clinical Trials in the Parallel Universe, *J Clin Studies*, 16(1), (2024).
36. Fang, L., Gong, Y., Hooker, AC., Lukacova, V., Rostami-Hodjegan, A., Sale, M., Grosser, S., Jereb, R., Savic, R., Peck, C. & Zaho, L. The Role of Model Master Files for Sharing, Acceptance and Communication with FDA, *AAPS J.*, 26:28 (2024) doi: 10.1208/s12248-024-00897-8